Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound (Nasdaq: MDWD) has announced the publication of its Phase II ChronEx study results for EscharEx® in treating Venous Leg Ulcers (VLU) in THE LANCET's eClinicalMedicine. The study, conducted across 20 medical centers in the US, Europe, and Israel, demonstrated EscharEx's superiority over non-surgical standard of care in debridement and promoting healthy granulation tissue.
Key findings include:
- 63.0% complete debridement rate for EscharEx vs. 30.2% for placebo and 13.3% for non-surgical standard of care
- Median time to complete debridement: 9 days for EscharEx vs. 63 days for placebo
- 50.0% incidence of complete cover with healthy granulation tissue for EscharEx vs. 25.6% for placebo
- Comparable safety profile to placebo and non-surgical standard of care
MediWound (Nasdaq: MDWD) has been awarded €16.25 million in blended funding from the European Innovation Council (EIC) Accelerator program. This funding will significantly advance the development of EscharEx, MediWound's innovative treatment for diabetic foot ulcers (DFUs). The package includes a €2.5 million grant and an investment with terms to be finalized.
This support will enable MediWound to expedite the market introduction of EscharEx by four years, addressing a substantial market of up to 34 million diabetic patients in the US and Europe who are at risk of developing DFUs. The funding not only recognizes EscharEx's potential impact on patients but also allows MediWound to develop it for DFUs in parallel with their advanced program for venous leg ulcers (VLUs).
Mölnlycke Health Care, a leading MedTech company, has announced a $15 million investment in MediWound (Nasdaq: MDWD) through a private investment in public equity (PIPE). MediWound specializes in next-generation enzymatic therapeutics for non-surgical wound debridement. The investment aligns with Mölnlycke's strategy to bring radical innovations to wound care and improve clinical outcomes.
As part of the collaboration agreement, Mölnlycke will have a representative attend MediWound's R&D Committee meetings and participate in potential strategic partnership discussions. This partnership aims to support Mölnlycke's mission to 'help free patients from the burden of wounds' and strengthen MediWound's strategic plans to create long-term value for stakeholders and improve patient care standards.
MediWound (Nasdaq: MDWD) has announced a $25 million strategic private placement financing, led by Mölnlycke Health Care with a $15 million investment. The company will sell 1,453,488 ordinary shares at $17.20 per share. The proceeds will be used to advance EscharEx pre-commercial activities, develop large-scale manufacturing capabilities, and support general corporate purposes.
Alongside the investment, MediWound and Mölnlycke have entered into a collaboration agreement, granting Mölnlycke specific rights, including representation in MediWound's R&D Committee and participation in potential strategic partnerships. The agreement includes a stand-still clause limiting Mölnlycke's ownership to 9.99% of MediWound's outstanding shares.
MediWound reported its Q1 2024 financial results, highlighting $5 million in revenue, compared to $3.8 million in Q1 2023, with a forecast of $24 million for the year. Gross profit decreased to $0.6 million from $0.8 million due to revenue mix changes. MediWound's new manufacturing facility is on track for mid-2024 completion. The EscharEx® Phase III trial will start in H2 2024. Net loss widened to $9.7 million, driven by financial expenses related to warrant revaluation. The company joins the Russell 3000® Index and has $36 million in cash reserves as of March 31, 2024.
The NexoBrid® US launch is progressing, with 30 burn centers placing initial orders. FDA reviews and military contracts are expected to influence future results. R&D and SG&A expenses decreased due to phase completion and operational efficiencies.
MediWound (Nasdaq: MDWD) will release its first quarter 2024 financial results on May 29, 2024. The report will cover the period ending March 31, 2024.
A conference call and live webcast are scheduled for the same day at 8:30 am Eastern Time. The call will discuss financial results, provide corporate updates, and include a Q&A session. Dial-in numbers for various regions and a webcast link are provided. An archived version of the webcast will be available on the MediWound website after the event.
FAQ
What is the current stock price of Mediwound (MDWD)?
What is the market cap of Mediwound (MDWD)?
